Navigation Links
AACR honors Hagop Kantarjian for outstanding clinical research
Date:4/8/2013

WASHINGTON, D.C. Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.

Kantarjian will receive the 18th Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research from the American Association for Cancer Research Tuesday. His award is one of six given to MD Anderson faculty at the annual meeting.

"As a highly accomplished individual investigator and the leader of a renowned department, Dr. Kantarjian's impact on the survival and well-being of leukemia patients is felt around the world," said Waun Ki Hong, M.D., head of MD Anderson's Division of Cancer Medicine and vice provost for clinical research. "He has earned this honor through years of dedicated effort."

Kantarjian's lecture, "Leukemia Research and Progress A Look Back at the Future," will be at 4 p.m. ET Tuesday, April 9, in the Walter E. Washington Convention Center.

"I am truly honored and humbled to be in the company of great men and women who, by their dedication to clinical research, have made seminal discoveries that have led to seismic changes in our understanding of cancer biology and therapeutics," Kantarjian said.

As a clinician and clinical researcher, Kantarjian has contributed to multiple improvements in the treatment of leukemia patients, including the development and testing of:

  • First- and second-generation BCR-ABL inhibitors, revolutionary new drugs for chronic myeloid leukemia (CML). Since the approval of Gleevec in 2001, these new treatments have raised the five-year survival rate of CML patients from 50 percent to 90 percent.

  • Combination therapies for acute lymphocytic leukemia that became standard of care and the single agent clofarabine, approved for ALL in 2005.

  • The epigenetic drug decitabine for myelodysplastic syndromes, potentially lethal blood malignancies that also can advance to acute myeloid leukemia (AML), approved for MDS in 2006.

  • FDA approval of ruxolitinib for myelofibrosis, an incurable and eventually lethal scarring of the bone marrow, the first approved treatment for the disease and the first to target the JAK2 protein. All clinical trials for the drug were led at MD Anderson.

"As with many individual awards, this honor reflects the efforts and accomplishments of MD Anderson's Department of Leukemia, which includes outstanding investigators across the full spectrum of leukemia," Kantarjian said.

Kantarjian has mentored many internationally recognized experts in the field, Hong said, many of whom are in the Department of Leukemia.

Overall during the past 12 years the department has been instrumental in discovering new, more effective combination treatments and in U.S. Food and Drug Administration approval of new drugs for CML (5), MDS and AML, ALL, chronic lymphocytic leukemia and myelofibrosis.

Two of the eight programs chosen for MD Anderson's Moon Shots Program are from the department. One addresses chronic lymphocytic leukemia and the other myelodysplastic syndromes and acute myeloid leukemia. The program is an unprecedented effort to accelerate the pace of converting scientific discoveries into clinical advances to reduce cancer deaths.

Kantarjian is also the Kelcie Margaret Kana Research Chair and associate vice president for global academic programs at MD Anderson. He received his medical degree from The American University of Beirut in Lebanon and then completed a fellowship at MD Anderson and joined the faculty in 1983. He has received numerous accolades, including the Outstanding Service to Mankind Award from the Leukemia Society of America.

Kantarjian, a member of the AACR since 1985, was on the editorial board of Clinical Cancer Research and serves on the boards of several other scientific journals, including the Journal of Clinical Oncology. He is also a member of the American Association for the Advancement of Science, the American Society of Hematology and the American Society for Clinical Oncology, where he serves on the board of directors. Kantarjian has authored or co-authored more than 1,000 peer-reviewed medical publications.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Amyotrophic Lateral Sclerosis Association honors Dr. Robert Baloh, M.D.
2. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
3. ASH honors Margaret A. Goodell, Ph.D., with 2012 William Dameshek Prize
4. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
5. Argentina honors Dr. Laurie H. Glimcher for enriching scientific cooperation
6. Speech-language researcher awarded top honors
7. Kentucky receives top honors in nations capital for health IT collaboration
8. Radiation Research Society honors 2 faculty
9. Bridges to Recovery Reaches Ten-Year Milestone as Premiere, Licensed Residential Behavioral Treatment Program and Honors Founding Medical Director Dr. Terry V. Eagan
10. Washington SmartCEO Honors NET ESOLUTIONS CORPORATION (NETE) as a Best-Run Company in Greater Washington
11. The Association for Gerontology in Higher Education honors new officers, fellows, awardees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has ... the Atlanta Football Host Committee (AFHC) for the 2018 College ... Jan. 8, 2018, at Mercedes-Benz Stadium in Atlanta, ... of the AFHC "I,m In" campaign, participating in many activities ... ...
Breaking Medicine Technology: